OVERVIEW

Targeting Epidermal Growth Factor Receptor in Non-Small Cell Lung Cancer: Advances in Treatment is organized by National Association for Continuing Education (NACE).

Start Date: Jun 15, 2019
Expiration Date: Jun 14, 2020

Target Audience: Oncologist and other clinicians that care for patients with EGFR NSCLC

Credit(s):
• 1.0 AMA PRA Category 1 Credit(s)™
• 1.0 AANP Contact Hour(s) which includes 0.75 pharmacology hours

Estimated Time To Complete CME Activity: 1.0 Hour

Summary:
It is estimated that more than 234,000 cases of lung cancer will be diagnosed and more than 154,000 lung cancer related deaths in 2018. Approximately 80-85% of patients with lung cancer are diagnosed with NSCLC. Historically, first-line treatment for NSCLC has been platinum-based chemotherapy. However, with the advent of genomic testing, the treatment of many cancers, including NSCLC, has transformed to a more personalized approach.

This activity will explore the need for testing for epidermal growth factor receptor (EGFR) mutations in patients with non-small cell lung cancer, the role of mechanisms of EGFR inhibitors, development of an individualized treatment strategy and the adverse effects of EGFR inhibitor treatment.

This webcast was recorded live at Conversations in Oncology 2019 and is being used with the permission of the presenters.

Learning Objectives:
After completing this program participants should be able to:
• Recognize the need for testing for epidermal growth factor receptor (EGFR) mutations in patients with non-small cell lung cancer (NSCLC)
• Recognize the role of mechanisms of resistance of EGFR inhibitors in the treatment of patients with NSCLC
• Integrate the latest clinical data on EGFR inhibitors when developing an individualized treatment strategy for patients with NSCLC
• Identify the adverse effects of EGFR inhibitor treatment in NSCLC